MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

Stock Information for MEI Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About MEI Pharma Inc.

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.